Literature DB >> 11287286

Establishment and characterization of an oral melanoma cell line (ME).

K W Chang1, S C Lin, S Y Chao, P C Kwan, C P Chiu, Y K Wong.   

Abstract

A new cell line, ME, has been established from a melanoma of the palatal mucosa. The cultured monolayer of cells was fusiform and melanin-producing. The cells were highly tumorigenic and metastatic in nude mice. The xenographic tumors resembled the original tumor in morphology, melanin production, and the expression of S-100 and HMB-45 antigens. The metaphase karyotype of ME indicated multiple aberrations of chromosomes 2, 3, 5, 7-11, 13, 19, 21 and X. A homozygous loss of the p16/MTS1 gene during the establishment of ME correlated with karyotypic evidence of chromosome 9 abnormalities. Absence of nm23 protein expression and elevated expression of CD44 protein (indicative of metastatic phenotypes) were demonstrated in primary and xenographic tumors. ME cells could be valuable in developing novel therapeutic strategies for oral melanoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287286     DOI: 10.1016/s1368-8375(00)00116-0

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  3 in total

1.  Genetic markers of oral malignant melanoma analysed by fluorescence in situ hybridisation (FISH).

Authors:  Chiara Baldovini; Anna L Tosi; Enrico Di Oto; Camilla Reggiani; Susanna Cappia; Christine M Betts; Carmine Gallo; Lisa Ricchieri; Roberto Cocchi; Maria P Foschini
Journal:  Virchows Arch       Date:  2011-06-29       Impact factor: 4.064

2.  Oral malignant melanoma diagnosed in an Iranian population over an 11-year period.

Authors:  Jahanfar Jahanbani; Aghdas Forouzandeh; Donya Sadri; Jila Mirlashari
Journal:  Oral Maxillofac Surg       Date:  2008-12

3.  Establishment and characterization of a cell line (DEOC-1) originating from a human malignant melanoma of the skin.

Authors:  Seiji Maeshima; Takashi Yamada; Kimihiro Kiyokane; Hiroshi Mori
Journal:  Hum Cell       Date:  2007-05       Impact factor: 4.174

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.